Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Osteoporosis Experts Discuss Bisphosphonate Holidays

Susan Bernstein  |  November 24, 2020

ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

Vanessa Caceres  |  November 24, 2020

ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge….

Dr. Blair Solow’s Picks for the Top RA Research Presented at ACR Convergence 2020

Elizabeth (Blair) Solow, MD  |  November 23, 2020

ACR CONVERGENCE 2020—Held Nov. 5–9, the ACR’s first fully virtual annual meeting provided participants with a vast repository of new research related to rheumatoid arthritis (RA). To help you sort through the noise, Elizabeth (Blair) Solow, MD, an assistant professor of medicine in the Division of Rheumatic Diseases at UT Southwestern Medical Center, Dallas, offered …

ACR Introduces Draft Guideline for RA Management

Jason Liebowitz, MD, FACR  |  November 23, 2020

Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.

ACR Convergence 2020

Lupus Immunology Findings Provide Insights for Rheumatologists

Vanessa Caceres  |  November 23, 2020

Chandra Mohan, MD, PhD, provided an update on the immunology behind SLE and research findings from the past decade.

COVID-19 Perspectives Shared in ACR Convergence Opening Session

Thomas R. Collins  |  November 23, 2020

ACR CONVERGENCE 2020—Eric Rubin, MD, PhD, took over as editor in chief of the New England Journal of Medicine in September 2019, just a few months before COVID-19 began taking over the world. Since then, Dr. Rubin’s perspective on the pandemic has been unlike that of any other person: He has led reviews of a…

ACR Convergence 2020

Treatment of Lupus Nephritis Continues to See Progress

Thomas R. Collins  |  November 23, 2020

Three doctors reported on advances in research & treatments for lupus nephritis.

After the 2020 Election, What’s in Store for Rheumatology Advocacy?

ACR Advocacy Staff  |  November 22, 2020

Despite high voter turnout and many new faces entering Congress, minimal power shifts in most levels of government will have implications for the ACR’s advocacy agenda in 2021.

Deborah Dyett Desir, MD, Joins ACR Executive Committee as Secretary

Kurt Ullman  |  November 22, 2020

To her new role as ACR Secretary, Dr. Desir brings extensive experience in both private practice and academic medicine, more than a decade of volunteer leadership experience in the ACR and a deep commitment to service.

ACR Advances Rheumatology Positions in American Medical Association Policies

From the College  |  November 22, 2020

At the American Medical Association House of Delegates Special Meeting held Nov. 13–17, 2020, the ACR’s delegation successfully led an effort to update AMA policies on home infusion and copay accumulators.

  • « Previous Page
  • 1
  • …
  • 170
  • 171
  • 172
  • 173
  • 174
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences